In the cohort, 91.8.% of the patients had ductal carcinoma, 37.3% had de novo metastatic disease, 41.6% had HR + HER2-, 33.9% HER2-positive and 24.4% TNBC. The gene discussed is ERBB2; the disease is metastatic neoplasm.